I-INR isoloko isetyenziselwa ukulinganisa umphumo we-anticoagulants yomlomo kwi-thromboembolic disease.I-INR ende ibonakala kwi-anticoagulants yomlomo, i-DIC, ukusilela kwe-vitamin K, i-hyperfibrinolysis kunye nokunye.I-INR efinyeziweyo idla ngokubonwa kwi-hypercoagulable states kunye nokuphazamiseka kwe-thrombotic.I-INR, ekwabizwa ngokuba yi-International Normalized Ratio, yenye yezinto zokuvavanya umsebenzi we-coagulation.I-INR isekwe kwi-PT reagent ukulinganisa i-International Sensitivity Index kwaye ibale isiphumo ngeefomula ezinxulumeneyo.Ukuba i-INR iphezulu kakhulu, kukho umngcipheko wokuphuma kwegazi okungalawulwayo.I-INR inokubeka iliso ngokufanelekileyo kwaye isebenzise umphumo wamachiza e-anticoagulant.Ngokuqhelekileyo, i-anticoagulant drug warfarin isetyenziswa, kwaye i-INR kufuneka ibekwe esweni ngalo lonke ixesha.Kuya kufuneka wazi ukuba ukuba i-warfarin isetyenziswa, i-INR kufuneka ibekwe iliso rhoqo.Izigulane ezine-venous thrombosis kufuneka zithathe i-warfarin ngomlomo, kwaye ixabiso le-INR kufuneka ligcinwe ngokubanzi kwi-2.0-2.5.Kwizigulane ezine-fibrillation ye-atrial, ixabiso le-inr ye-warfarin yomlomo ngokuqhelekileyo igcinwe phakathi kwe-2.0-3.0.Amaxabiso e-INR angaphezulu kwe-4.0 anokubangela ukuphuma kwegazi okungalawulekiyo, ngelixa ixabiso le-INR elingaphantsi kwe-2.0 aliboneleli nge-anticoagulation esebenzayo.
Icebiso: qhubeka uye esibhedlele esiqhelekileyo ukuze uxilongwe, kwaye uthobele ilungiselelo likagqirha oqeqeshiweyo.
I-Beijing Succeeder ekhethekileyo kwi-thrombosis kunye neemveliso zokuxilonga i-hemostasis kwimarike yehlabathi.
Njengenye yeebrendi eziphambili eChina Diagnostic market of Thrombosis and Hemostasis .I-SUCCEEDER inamava amaqela e-R&D, iMveliso, iNtengiso yoThengiso kunye neNkonzo yokuBonelela abahlalutyi be-coagulation kunye ne-reagents, abahlalutyi begazi le-rheology ESR kunye ne-HCT abahlalutyi beplatelet aggregation analyzers kunye ne-FDA Certification kunye ne-CET13485 idwelisiwe.
Ikhadi leshishini
Chinese WeChat
WeChat yesiNgesi